RightFit
Not yet recruitingPhase 4

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests how Lumify eye drops affect eye redness, pressure inside the eye, and eyelid position. It is for adults with glaucoma who already use brimonidine eye drops. Glaucoma damages the nerve that carries signals from the eye to the brain.

Glaucoma represents a group of conditions that cause damage to the optic nerve and can lead to irreversible vision loss. Current treatments are aimed at lowering intraocular pressure while minimizing medication side effects. Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) is an FDA-approved medication for alleviating eye redness, a common side effect of glaucoma medications. The purpose of this study is to evaluate the effect of Lumify™ on eye redness, intraocular pressure, and eyelid position in patients with glaucoma who are already using the Brimonidine 0.1%, 0.15% or 0.2% eye drops.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Be older than 18.
  • Have primary open-angle glaucoma, a type of glaucoma.
  • Be willing and able to agree to join after learning about the study.
  • Currently use brimonidine eye drops at 0.1%, 0.15%, or 0.2%, and have used them for more than 6 weeks.

Who can't join

  • Are pregnant.
  • Are a prisoner.
  • Have a known allergy or sensitivity to brimonidine.
  • Have had surgery in the past 6 months.
  • Have ever had eyelid surgery or Botox.
  • Have another major eye condition that the study doctor thinks could affect eye redness, eye pressure, or eyelid position.
  • Cannot sit comfortably for 30 minutes.
  • Have used eye-whitening drops, medicines for a stuffy nose, allergy medicines called antihistamines, or phenylephrine drops that widen the pupil within 1 week of the study.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

Inclusion Criteria: * Age \> 18 years * Diagnosis of primary open angle glaucoma * Willing and able to give informed consent * Current and greater than 6 weeks of brimonidine 0.2%, 0.15% or 0.1% use Exclusion Criteria: * Pregnancy * Prisoners * Known allergy or sensitivities to brimonidine * No surgery within the past 6 months * No history of lid surgery or botox * Any other significant ophthalmologic disorder or condition with relevant effect on ocular redness, IOP, or eyelid position as evaluated by principal investigator * Inability to sit comfortably for 30 minutes * Prior use of eye whiteners (eg, vasoconstrictors), decongestants, antihistamines, or phenylephrine dilating drops within 1 week of study

Study sites (1)

LA